Are you Dr. Rachman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7601 Canby Ave
Ste 7
Reseda, CA 91335Phone+1 818-757-1919Fax+1 818-757-3134
Summary
- Dr. Ilya Rachman, MD is a board certified internist in Reseda, California. He is currently licensed to practice medicine in California. He is affiliated with Providence Cedars-Sinai Tarzana Medical Center and Cedars-Sinai Medical Center.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Illinois College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026- American Board of Internal Medicine Internal Medicine
Clinical Trials
- IMX-110 in Patients With Advanced Solid Tumors Start of enrollment: 2018 Feb 15
Publications & Presentations
PubMed
- 70 citationsNanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.Can Sarisozen, Shekhar Dhokai, Edcar G. Tsikudo, Ed Luther, Ilya M. Rachman
European Journal of Pharmaceutics and Biopharmaceutics. 2016-11-01 - 43 citationsAnti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicinAbraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, Vladimir P. Torchilin
Journal of Drug Targeting. 2013-10-28 - 12 citationsLupron-induced maniaMichael Rachman, David A. S. Garfield, Ilya M. Rachman, Rochelle S. Cohen
Biological Psychiatry. 1999-01-15
Press Mentions
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 26th, 2024- Positive Early Results Seen for CAR T-cell Therapy for Myeloma in TrialMay 1st, 2023
- Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment PotentialMarch 23rd, 2023
- Join now to see all
